 |
| Contact us |
|
| For media professionals: |
This contact information is for media professionals only. If you are not a member of the news media, please contact us via the phone number or email link at the bottom of the page.
|
|
| U.S. Communications: |
Lisa Buffington
(908) 981-6569
US.media-relations@sanofi-aventis.com
sanofi-aventis U.S.
55 Corporate Drive
Bridgewater, NJ 08807
Tel: 800-981-2491
|
| Via email |
|
|
|
|
 | 2005 Press Releases |
|
 | Press releases are intended for journalists, investors and shareholders. |
|
|
|
| December 13, 2005 |
| PLAVIX® (clopidogrel bisulfate) recommended as effective cardiovascular risk reduction treatment for patients with established Peripheral Arterial Disease (P.A.D.) |
|
|
|
|
| December 08, 2005 |
| Interim analysis of phase III study shows TAXOTERE®-based regimens with HERCEPTIN® significantly improved disease free survival in women with early-stage HER2-positive breast cancer |
|
|
|
|
| December 06, 2005 |
| New analysis ranks America’s worst cities for respiratory infections |
|
|
|
|
| December 02, 2005 |
| FDA Grants Priority Review to Taxotere® for the Supplemental New Drug Application for Advanced Gastric Cancer |
|
|
|
|
| November 16, 2005 |
| New England Journal of Medicine publishes the RIO-Lipids study |
|
|
|
|
| November 15, 2005 |
| Analysis from several clinical studies show dronedarone appears to be consistently safe and effective in maintaining normal sinusal rhythm and ventricular rate control in patients with cardiac arrhythmia |
|
|
|
|
| November 15, 2005 |
| Study shows that intra-articular hyaluronate therapy HYALGAN® (sodium hyaluronate) is effective in treating chronic shoulder pain due to osteoarthritis |
|
|
|
|
| November 08, 2005 |
| Third quarter 2005: Adjusted EPS up 27.4%, net sales up 11.0% on a comparable basis - First 9 months of 2005: Adjusted EPS up 26.6%, net sales up 11.0% on a comparable basis |
|
|
|
|
| November 07, 2005 |
| New data show long-term (52 week) use of ALVESCO® (ciclesonide) had a low incidence of oropharyngeal side effects in patients with mild-to-moderate asthma |
|
|
|
|
| October 20, 2005 |
| EXUBERA® inhaled insulin improves blood sugar levels in adults with type 2 diabetes better than diabetes pills alone |
|
|
|
|
| October 07, 2005 |
| AMBIEN CR™ now available in the US |
|
|
|
|
| September 29, 2005 |
| Sanofi-aventis provides relief to hurricane victims |
|
|
|
|
| September 29, 2005 |
| Hearing date set on motion for preliminary injunction in ALLEGRA® (fexofenadine hcl) patent infringement case |
|
|
|
|
| September 20, 2005 |
| FDA accepts filed pre-market approval supplement to expand the indication for HYALGAN® (sodium hyaluronate) to include shoulder pain due to osteoarthritis |
|
|
|
|
| September 15, 2005 |
| INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER |
|
|
|
|
| September 14, 2005 |
| Study Finds Alvesco® (ciclesonide) Did Not Affect HPA-Axis Function in Patients with Moderate-to-Severe Persistent Asthma |
|
|
|
|
| September 12, 2005 |
| Sanofi-aventis Group enters agreement with Prasco Laboratories to market generic versions of ALLEGRA® (fexofenadine HCl) |
|
|
|
|
| September 08, 2005 |
| FDA Advisory Committee recommends Approval of EXUBERA® for use in adults with type 1 and type 2 diabetes |
|
|
|
|
| September 06, 2005 |
| AMBIEN CR™ (zolpidem tartrate extended-release tablets) CIV receives FDA Approval for the treatment of insomnia |
|
|
|
|
| August 31, 2005 |
| Strong growth in 2005 first half adjusted EPS : up 26.1% at €2.22. Increase in full year adjusted EPS guidance. Positive phase IIb/III results for 6 products |
|
|
|
|
| August 18, 2005 |
| Taxotere® Significantly Improves Survival Compared with paclitaxel In Women With Advanced Breast Cancer |
|
|
|
|
| August 15, 2005 |
| The U.S. Food and Drug Administration approves ACTONEL® WITH CALCIUM |
|
|
|
|
| August 02, 2005 |
| Sanofi-aventis Issues Strong Support for Voluntary “Guiding Principles” on DTC Advertising |
|
|
|
|
| July 27, 2005 |
| ALLEGRA-D® 24 HOUR (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) EXTENDED RELEASE TABLETS NOW AVAILABLE FOR SEASONAL ALLERGY SUFFERERS |
|
|
|
|
| July 19, 2005 |
| Strong net sales growth in the first half of 2005: 11.0% on a comparable basis - Further increase in market share in the second quarter |
|
|
|
|
| June 30, 2005 |
| Sports Legend Tony Gwynn Teams up with Former Baseball Champions to Raise Awareness of Deep-Vein Thrombosis (DVT) in the National Educational Campaign, "DVT Blood Clots: Know The Stats. Know Your Risk.” |
|
|
|
|
| June 28, 2005 |
| PANEL OF EXPERTS AGREE THAT BONE MINERAL DENSITY IS NO LONGER ENOUGH |
|
|
|
|
| June 23, 2005 |
| RIMONABANT ACCEPTED FOR FILING BY THE FDA |
|
|
|
|
| June 14, 2005 |
| Data presented at American Diabetes Association Scientific Sessions support Exubera® Efficacy and Safety Profile in Type 1 and Type 2 Diabetes |
|
|
|
|
| June 13, 2005 |
| DATA PRESENTED AT ADA SHOWED THAT BASAL INSULIN THERAPY WITH LANTUS® ACHIEVED TARGET GLYCEMIC CONTROL IN POORLY CONTROLLED TYPE 2 DIABETES |
|
|
|
|
| June 13, 2005 |
| Clinical Study Results Demonstrated Greater Flexibility With Mealtime Dosing of Apidra® When Compared to Regular Human Insulin |
|
|
|
|
| June 13, 2005 |
| Lantus® Add-on to Oral Monotherapy Therapy Showed Improved Glycemic Control in Type 2 Diabetes Patients Compared to Oral Actos Add-on to Oral Therapy |
|
|
|
|
| June 12, 2005 |
| Rimonabant study shows significant improvements in HbA1c and cardiometabolic risk factors in people with type 2 diabetes |
|
|
|
|
| June 08, 2005 |
| Prospective Study Published in Diabetes Care Confirms Basal Therapy with Lantus® Improves Glycemic Control in Patients with Type 2 Diabetes Poorly Controlled on Prior Insulin Regimens |
|
|
|
|
| June 02, 2005 |
| Landmark Taxotere® Study in Early Stage Breast Cancer Published in the New England Journal of Medicine |
|
|
|
|
| May 31, 2005 |
| Sanofi-aventis Annual General Meeting |
|
|
|
|
| May 25, 2005 |
| UROXATRAL® (alfuzosin HCl) STUDY SHOWS IMPROVEMENT UP TO TWO YEARS IN LOWER URINARY TRACT SYMPTOMS AND SEXUAL FUNCTION IN MEN WITH ENLARGED PROSTATES |
|
|
|
|
| May 24, 2005 |
| New Study Demonstrates Clinical Efficacy of Telithromycin Superior to Standard First-Line Antibiotic Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia (CAP) |
|
|
|
|
| May 23, 2005 |
| New Data Demonstrate Alvesco® (ciclesonide) Significantly Reduces Oral Corticosteroid Use in Patients with Severe, Persistent Asthma |
|
|
|
|
| May 15, 2005 |
| Taxotere® Regimen Demonstrates Significant Survival Benefit In The Treatment Of Advanced Gastric Cancer |
|
|
|
|
| May 13, 2005 |
| Sanofi-aventis 2005 first-quarter net sales |
|
|
|
|
| May 10, 2005 |
| New Eloxatin® and Taxotere® research to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) |
|
|
|
|
| May 10, 2005 |
| Rescheduling of the pre-trial order date in the United States Plavix® litigation |
|
|
|
|
| April 15, 2005 |
| Sanofi-aventis affirms its commitment to Access to Medicines in the "Southern countries", with a policy of tiered drug prices geared to populations incomes |
|
|
|
|
| April 11, 2005 |
| FDA issues approvable letter for AMBIEN CR™ (zolpidem tartrate extended release) C IV for the treatment of Insomnia |
|
|
|
|
| April 07, 2005 |
| Sanofi-aventis Statement |
|
|
|
|
| April 01, 2005 |
| Sanofi-aventis concludes €10 billion in medium-term credit agreements with its banks to refinance the Aventis acquisition financing entered into in April 2004 |
|
|
|
|
| March 30, 2005 |
| Rescheduling of the pre-trial order date in the United States Plavix® litigation |
|
|
|
|
| March 24, 2005 |
| Sanofi-aventis joins the fight against tuberculosis in South Africa |
|
|
|
|
| March 22, 2005 |
| Court grants Sanofi-aventis's request for Order of Prohibition in the Canadian Plavix® litigation |
|
|
|
|
| March 22, 2005 |
| New Data Demonstrate Alvesco® (ciclesonide) Significantly Improves Quality-of-Life for Patients with Mild-to-Moderate Asthma |
|
|
|
|
| March 22, 2005 |
| New Data Demonstrate Alvesco® (ciclesonide) Has a Low Incidence of Mouth- and Throat- Related Side Effects in Pediatric Asthma Patients |
|
|
|
|
| March 11, 2005 |
| SANOFI-AVENTIS SUES NOVOPHARM FOR PATENT INFRINGEMENT IN CANADA |
|
|
|
|
| March 09, 2005 |
| CLOPIDOGREL IMPROVED CORONARY PERFUSION AND REDUCED MORTALITY IN ACUTE HEART ATTACK |
|
|
|
|
| March 02, 2005 |
| PFIZER AND THE SANOFI-AVENTIS GROUP SEEK APPROVAL TO MARKET EXUBERA® IN THE UNITED STATES |
|
|
|
|
| March 01, 2005 |
| Sanofi-aventis 2004 Results |
|
|
|
|
| February 24, 2005 |
| First Pilot Study to Show Benefit Using Hyalgan® (sodium hyaluronate) in the Treatment of Osteoarthritis of the Ankle |
|
|
|
|
| February 24, 2005 |
| Creation of the sanofi-aventis European Works Council |
|
|
|
|
| February 23, 2005 |
| Update of the Patent Litigation Schedule in the United States for Plavix® |
|
|
|
|
| February 18, 2005 |
| Sanofi-aventis world solidarity day on behalf of South East Asia - January 25, 2005: "Sharing in solidarity" |
|
|
|
|
| February 17, 2005 |
| Sanofi-aventis announces commercial availability of twice-yearly Eligard® |
|
|
|
|
| February 02, 2005 |
| Sanofi-aventis receives FDA approval for new Eloxatin™ formulation |
|
|
|
|
| January 26, 2005 |
| 2004 pro forma combined net sales: up 10.0% on a comparable basis |
|
|
|
|
| January 25, 2005 |
| Sanofi-aventis “Solidarity Day” offers additional aid, assistance to Southeast Asia “Sharing in solidarity” |
|
|
|
|
| January 25, 2005 |
| Plavix® patent |
|
|
|
|
| January 19, 2005 |
| The European Commission imposes a fine on certain MCAA producers |
|
|
|
|
| January 11, 2005 |
| New Together Rx Access™ Card offers Americans with no prescription drug coverage savings at the pharmacy counter |
|
|
|
|
| January 11, 2005 |
| Taxotere® (docetaxel) receives 2 new European approvals for treatment of breast cancer |
|
|
|
|
| January 10, 2005 |
| Aventis Pasteur, the vaccine division of the sanofi-aventis Group, changes its name to sanofi Pasteur |
|
|
|
|
| January 10, 2005 |
| Sanofi-aventis and Regeneron Pharmaceuticals reaffirm development commitment |
|
|
|
|
| January 06, 2005 |
| Update of the patent litigation schedule in the United States for Plavix® |
|
|
|
|
| January 03, 2005 |
| Sanofi-aventis provides Humanitarian Aid for South-East Asia |
|
|
|
|
|
|
